Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 52-Week High – Time to Buy?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) hit a new 52-week high on Tuesday . The stock traded as high as $40.00 and last traded at $40.0980, with a volume of 3519760 shares. The stock had previously closed at $27.58.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CNTA. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. B. Riley Financial lifted their target price on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. TD Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Finally, Wolfe Research initiated coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $40.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Centessa Pharmaceuticals Price Performance

The stock has a fifty day moving average of $25.96 and a two-hundred day moving average of $25.12. The stock has a market cap of $5.82 billion, a price-to-earnings ratio of -21.78 and a beta of 1.54. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 120,029 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the completion of the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. This trade represents a 65.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the sale, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 349,073 shares of company stock valued at $9,429,412 in the last ninety days. 7.09% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC raised its holdings in Centessa Pharmaceuticals by 34.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after purchasing an additional 3,747,475 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in Centessa Pharmaceuticals by 12.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock valued at $282,156,000 after purchasing an additional 1,246,741 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Centessa Pharmaceuticals by 24.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock valued at $134,480,000 after buying an additional 1,045,750 shares in the last quarter. Siren L.L.C. increased its position in shares of Centessa Pharmaceuticals by 24.8% in the fourth quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock valued at $100,728,000 after buying an additional 800,000 shares in the last quarter. Finally, Commodore Capital LP raised its stake in shares of Centessa Pharmaceuticals by 39.3% during the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after buying an additional 930,711 shares during the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.